Furthermore, aberrant Mfn2 expression has been reported in metabolic disorders, including type 2 diabetes mellitus and insulin resistance [73], for which Exenatide and GLP-1R agonists are effective in treatments [76]. This evidence concerns the gene MFN2 and type 2 diabetes mellitus.